HopeStage
Back to all studies
Active Not RecruitingNCT06029296

Diclofenac as a KMO Inhibitor

Medication studyAges 21–65United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 21 years to 65 years.

Listed locations
CatonsvilleSee all locations and recruitment
Study phase
Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 31, 2024
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
12
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Locations
United States
Age range
From 21 Years to 65 Years
Official registry ID
NCT06029296
Official title
Show the full official title

Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder

Recruitment & locations

Not recruiting

Catonsville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Does this study involve medication?

Yes. The study involves medication, including Diclofenac and Placebo.

Who can participate?

Listed age limits: 21 years to 65 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies